AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

IMUGENE LIMITED Board/Management Information 2012

Oct 1, 2012

65124_rns_2012-10-01_4e059c22-4fd2-44bc-a7f3-26847cefae20.pdf

Board/Management Information

Open in viewer

Opens in your device viewer

==> picture [207 x 81] intentionally omitted <==

ASX RELEASE 2 October 2012

Resignation of Director

Imugene Limited (Company) announces the resignation of Roger Steinepreis as a Director of the Company effective 1 October 2012.

The Board thanks Mr. Steinepreis for his contribution to the Company and wishes him well for the future.

ENDS

For more information please visit the Imugene Website www.imugene.com or contact:

Dr Warwick Lamb Managing Director +61 (0) 3 9416 0032

About Imugene

Imugene Limited (ASX:IMU) is commercialising drug delivery applications based on its novel buccal (drugs administered via the cheek) Linguet™technology. Linguet™ is a patient friendly and cost effective system used to deliver established pharmaceutical and nutraceutical products. Imugene also currently specialises in the development and commercialisation of novel animal health products for pigs and poultry. The range of products under development includes vaccines to prevent important livestock diseases and productivity enhancers to improve the economics of raising commercial livestock.